MYGN stock forecast
Our latest prediction for Myriad Genetics, Inc.'s stock price was made on the Aug. 1, 2019 when the stock price was at 45.01$.
In the short term (2weeks), MYGN's stock price should outperform the market by 1.23%. During that period the price should oscillate between -6.68% and +8.54%.
In the medium term (3months), MYGN's stock price should outperform the market by 0.38%. During that period the price should oscillate between -14.34% and +19.71%.Get email alerts
About Myriad Genetics, Inc.
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
At the moment the company generates 813M USD in revenues.
On its last earning announcement, the company reported a loss of -0.36$ per share.
The book value per share is 13.61$
Three months stock forecastAug. 1, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|